GFA
PACB icon

Gallagher Fiduciary Advisors’s Pacific Biosciences PACB Stock Holding History

Gallagher Fiduciary Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,486
Closed -$43.9K – 349
2025
Q4 		$43.9K Buy
23,486
+1,813
+8% +$3.48K ﹤0.01% 325
2025
Q3 		$27.7K Buy
21,673
+385
+2% +$521 ﹤0.01% 306
2025
Q2 		$26.4K Buy
21,288
+3,899
+22% +$4.5K ﹤0.01% 324
2025
Q1 		$20.5K Buy
17,389
+339
+2% +$520 ﹤0.01% 302
2024
Q4 		$31.2K Buy
17,050
+3,104
+22% +$6.06K 0.01% 297
2024
Q3 		$23.7K Buy
+13,946
New +$22.9K ﹤0.01% 273

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Gallagher Fiduciary Advisors's PACB Position: Q1 2026 in Review

Gallagher Fiduciary Advisors sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 23,486 shares — an estimated $43.9K sold.

Gallagher Fiduciary Advisors first reported a position in PACB in Q3 2024 and held it in 6 quarters. The position peaked at $43.9K in Q4 2025. 231 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Gallagher Fiduciary Advisors reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
  • Gallagher Fiduciary Advisors sold 23,486 Pacific Biosciences shares in Q1 2026, an estimated $43.9K.
  • Gallagher Fiduciary Advisors first reported a position in Pacific Biosciences in Q3 2024 and held it in 6 quarters.
  • Gallagher Fiduciary Advisors's Pacific Biosciences position peaked at $43.9K in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Gallagher Fiduciary Advisors's 13F filing for Q1 2026, filed 15 May 2026.